title: An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes.
abstract: OBJECTIVE
  We sought to determine whether asymmetric dimethylarginine (ADMA) inhibits nitric oxide (NO) elaboration in cultured human endothelial cells and whether this is associated with the activation of oxidant-sensitive signaling mediating endothelial adhesiveness for monocytes.
  
  
  BACKGROUND
  Endothelial NO elaboration is impaired in hypercholesterolemia and atherosclerosis, which may be due to elevated concentrations of ADMA, an endogenous inhibitor of NO synthase.
  
  
  METHODS
  Human umbilical vein endothelial cells (ECV 304) and human monocytoid cells (THP-1) were studied in a functional binding assay. Nitric oxide and superoxide anion (O2-) were measured by chemiluminescence; ADMA by high pressure liquid chromatography; monocyte chemotactic protein-1 (MCP-1) by ELISA and NF-KB by electromobility gel shift assay.
  
  
  RESULTS
  Incubation of endothelial cells with ADMA (0.1 microM to 100 microM) inhibited NO formation, which was reversed by coincubation with L-arginine (1 mM). The biologically inactive stereoisomer symmetric dimethylarginine did not inhibit NO release. Asymmetric dimethylarginine (10 microM) or native low-density lipoprotein cholesterol (100 mg/dL) increased endothelial O2- to the same degree. Asymmetric dimethylarginine also stimulated MCP-1 formation by endothelial cells. This effect was paralleled by activation of the redox-sensitive transcription factor NF-KB. Preincubation of endothelial cells with ADMA increased the adhesiveness of endothelial cells for THP-1 cells in a concentration-dependent manner. Asymmetric dimethylarginine-induced monocyte binding was diminished by L-arginine or by a neutralizing anti-MCP-1 antibody.
  
  
  CONCLUSIONS
  We concluded that the endogenous NO synthase inhibitor ADMA is synthesized in human endothelial cells. Asymmetric dimethylarginine increases endothelial oxidative stress and potentiates monocyte binding. Asymmetric dimethylarginine may be an endogenous proatherogenic molecule.
authors: Section of Vascular Medicine, Stanford University School of Medicine, California 94305-5406, USA.
authors: R H
authors: RH
authors: Böger
authors: S M
authors: SM
authors: Bode-Böger
authors: P S
authors: PS
authors: Tsao
authors: P S
authors: PS
authors: Lin
authors: J R
authors: JR
authors: Chan
authors: J P
authors: JP
authors: Cooke
mesh_terms: D001120:Arginine / Q000031:analogs & derivatives* / Q000378:metabolism; D002448:Cell Adhesion; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000032:analysis; D004730:Endothelium, Vascular / Q000502:physiology*; D006801:Humans; D009000:Monocytes / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D018384:Oxidative Stress
chemical_list: D018932:Chemokine CCL2; D001120:Arginine; D019001:Nitric Oxide Synthase